secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-11-25T23:59:59+00:00
Accession:  0001193125-25-294108
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Aptose Biosciences to be acquired by Hanmi Pharmaceutical for C$2.41 per share in cash
--------------------------------------------------------------------------------

- Hanmi subsidiary will acquire all outstanding Aptose shares at C$2.41 each, a 28% premium over the 30-day VWAP of C$1.88 on TSX.
- Aptose board unanimously recommends the arrangement after unanimous recommendation from a special committee of independent directors.
- Transaction requires approval by two-thirds of votes cast and minority approval excluding Hanmi affiliates; special meeting by Jan 16, 2026.
- Non-solicitation provisions with a C$300,000 expense fee payable to Hanmi if agreement terminated under certain conditions.
- Post-closing, Aptose shares will be delisted from TSX and the company will cease reporting under Canadian securities legislation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000119312525294108/0001193125-25-294108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000119312525294108/d25723d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-294108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer